The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. PTC Therapeutics disavows any obligation to update the information contained in such press releases after the date of their issuance.


Date Title and Summary View
Sep 07, 2022 PTC Therapeutics' 2022 STRIVE Awards Program Funds Initiatives Supporting the Duchenne Patient Community
- 2022  recipients include patient advocacy organizations from Brazil , Greece , Turkey , and the U.K. - SOUTH PLAINFIELD, N.J. , Sept. 7, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the four recipients of its 2022 STRIVE Awards for Duchenne Muscular Dystrophy.
Sep 01, 2022 PTC Therapeutics to Participate at Upcoming Investor Conferences
SOUTH PLAINFIELD, N.J. , Sept. 1, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the following conferences:     Wells Fargo 17 th Annual Healthcare Conference Thursday, Sept. 8 , at 1:55 p.m.
Aug 04, 2022 PTC Therapeutics Provides a Corporate Update and Reports Second Quarter Financial Results
  - Total revenue of $166 million , representing 42% year-over-year growth –  - Upstaza™ gene therapy granted marketing authorization by European Commission for treatment of AADC deficiency with first commercial patient treated – SOUTH PLAINFIELD, N.J. , Aug.
Jul 21, 2022 PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2022 Financial Results
SOUTH PLAINFIELD, N.J. , July 21, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its second quarter 2022 financial results and provide an update on the company's business and outlook on Thursday, Aug.
Jul 20, 2022 Upstaza™ Granted Marketing Authorization by European Commission as First Disease-Modifying Treatment for AADC Deficiency
- PTC Therapeutics to launch first gene therapy directly administered into the brain - SOUTH PLAINFIELD, N.J. , July 20, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Upstaza™ (eladocagene exuparvovec) was granted marketing authorization by the European Commission
Jun 20, 2022 PTC Therapeutics to Host Call to Review Topline Results from Study 041 for Translarna™ (ataluren) in Nonsense Mutation Duchenne Muscular Dystrophy
SOUTH PLAINFIELD, N.J. , June 20, 2022 /PRNewswire/ -- PTC Therapeutics , Inc. (NASDAQ: PTCT) will host a conference call Tuesday, June 21 st at 8:00 a.m. E.T. to review topline results from Study 041 of Translarna™ (ataluren) in patients with nonsense mutation Duchenne muscular dystrophy.
Jun 09, 2022 Biotech Investment Veteran Alethia Young Joins PTC Therapeutics' Board of Directors
SOUTH PLAINFIELD, N.J. , June 9, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the election of Alethia Young to the company's Board of Directors. Ms. Young has more than 20 years of experience in healthcare and biotech equity research and investing.
Jun 06, 2022 PTC Therapeutics to Participate at William Blair 42nd Annual Growth Stock Conference
SOUTH PLAINFIELD, N.J. , June 6, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company overview at the William Blair 42 nd Annual Growth Stock Conference on Thursday, June 9 at 2:20 p.m. ET      The presentation will be webcast live on the
Jun 03, 2022 Preliminary Results Presented at ASCO Demonstrated Promising Clinical Efficacy with Unesbulin in Leiomyosarcoma Study
- Results highlight strength of PTC Therapeutics' scientific platform in targeting difficult-to-treat rare cancer types - SOUTH PLAINFIELD, N.J. , June 3, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced encouraging preliminary safety and efficacy results from its Phase 1B
May 31, 2022 FDA Approves Label Extension for Evrysdi® for Infants with Spinal Muscular Atrophy Under 2 Months Old
- Evrysdi is the first and only at-home administered treatment for patients living with SMA - - Evrysdi has proven efficacy in babies, children and adults with more than 5,000 patients treated to date - SOUTH PLAINFIELD, N.J. , May 31, 2022 /PRNewswire/ -- PTC Therapeutics, Inc.